FDA approves Alnylam's Amvuttra, competing with Vyndaqel

FDA approves Alnylam's Amvuttra for treating ATTR-CM, challenging market leaders.

The U.S. Food and Drug Administration (FDA) has authorized Alnylam Pharmaceuticals' injectable medicine, Amvuttra (vutrisiran), for the therapy of a rare, life-threatening heart disease called transthyretin amyloid cardiomyopathy (ATTR-CM). The approval represents a new category of therapy in a market led at present by Pfizer's block-buster medicine, Vyndaqel.

ATTR-CM is a disease resulting from the buildup of defective transthyretin proteins in the heart, leading to heart failure. The FDA approval of Amvuttra is a significant milestone for Alnylam, as the drug is intended to lower the levels of the disease-causing protein, providing a new way to treat the disease. In contrast to current drugs like Vyndaqel and Attruby by BridgeBio, that act through stabilizing the transthyretin protein, Amvuttra acts upon the root of the problem by reducing the creation of the toxic protein at its source.

This approval represents a significant milestone for Amvuttra, previously approved in 2022 for the treatment of nerve damage associated with ATTR-CM. The new indication for Amvuttra positions it as the first medicine to be approved to address both cardiac and neurological symptoms of the disease, offering more therapeutic choices for patients.

The market for ATTR-CM treatment is expected to top over $11 billion in revenue by 2032 and promises high potential for Amvuttra. Alnylam hopes the approval will not just make the company profitable but also give it the financial support to launch its next wave of therapies.

With this new approval, Amvuttra is set to disrupt the incumbent players in the ATTR-CM market, and Alnylam is optimistic that it can gain a meaningful share in this fast-growing therapeutic area.